Rosen Law Firm Advocates for Bolt Biotherapeutics Investors Before Critical Class-Action Deadline

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) – Investors who have purchased securities from Bolt Biotherapeutics, Inc. BOLT are being urged by Rosen Law Firm, a globally recognized investor rights advocacy group, to enlist legal counsel prior to a looming deadline. This call to action addresses the class period between February 5, 2021, and May 14, 2024, with the critical cut-off date set for September 3, 2024, to join the securities class action initiated by the firm.

The Allegations Against Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a company with its roots in clinical-stage immuno-oncology, is currently challenged by allegations that could significantly impact investor returns. Specializing in the innovation, development, and hopeful release of cutting-edge pharmaceuticals, the company operates from its base in Redwood City, California. Despite the firm's promising endeavors, it now finds itself at the center of a securities class action case that claims misinformation and omissions during the designated class period.

Investor Reminders and Legal Recourse

Rosen Law Firm continues its tradition of safeguarding investor rights, underscored by its recent reminder to BOLT shareholders. Its pursuit of fairness and transparency in the marketplace is reflected in the firm's commitment to hold Bolt Biotherapeutics accountable. Shareholders who recognize their possible exposure during the class period are encouraged to contact Rosen Law Firm for representation. As the litigation unfolds, the outcome of this action has the potential to set a substantial precedent for corporate obligations to shareholders and the enforcement of investor rights on a broader scale.

Rosen, Bolt, Securities